Business

Swedish DPI company Iconovo said that the United States Patent and Trademark Office (USPTO) has issued a notice of allowance regarding a patent covering Iconovo’s ICOres reservoir-based dry powder inhaler. The patent, titled "Dry Powder Inhaler," describes the design of the ICOres device. The company was granted a Japanese patent for ICOres in November 2019 and has … [Read more...] about Iconovo gets US patent covering the ICOres DPI

Virpax Pharmaceuticals said that it has acquired exclusive North American rights to Nanomerics' MMS019 nasal powder, which it calls a "high density molecular masking spray" and which is intended to block viruses from taking hold in the respiratory tract. Virpax said that MMS019 is in preclinical development for the prevention of COVID-19, seasonal flu, and other … [Read more...] about Virpax licenses Nanomerics’ MM2019 “molecular masking” nasal powder

Medical Developments International (MVP) has announced that it will buy back the European Union rights to its Penthrox methoxyflurane inhaler from Mundipharma for €3 million, plus a 5% royalty up to a maximum of €5 million. The companies plan a 6-month transition period beginning September 1, 2020. Penthrox is approved throughout Europe for the emergency treatment … [Read more...] about Medical Developments International buys back European Union rights to Penthrox inhaler from Mundipharma

According to Lannett, the company has signed an agreement with Chinese inhaled drug developer Respirent for exclusive rights to distribute Respirent's generic version of GSK's Flovent Diskus fluticasone propionate DPI, which is in early development. In October 2019, Lannett announced a US distribution deal with Respivent for that company's generic version of GSK's … [Read more...] about Lannett gets rights to distribute Respirent’s generic Flovent Diskus in the US

AstraZeneca has announced that the first doses of its FluMist Quadrivalent live intranasal flu vaccine for the 2020-2021 US influenza season have shipped. FluMist Quadrivalent is approved for use in children over the age of 2 and adults up to age 49. The company said that it has increased planned production of the vaccine by more than 25% in response to … [Read more...] about AstraZeneca increases production of FluMist Quadrivalent for 2020-2021 flu season

TFF Pharmaceuticals announced that the company has raised $25.9 million in a private placement, with the funds to be used to "to accelerate the expansion of the company’s internal development portfolio beyond its programs for voriconazole and tacrolimus inhalation powders." Earlier this year, the company announced that it was working on a universal flu vaccine in … [Read more...] about TFF Pharmaceuticals raises almost $26 million

Biohaven Pharmaceutical will receive up to $250 million from Royalty Pharma on closing of a deal to fund development of its zavegepant (formerly vazegepant) calcitonin gene-related peptide (CGRP) receptor antagonist program, which includes intranasal zavegepant, the companies said. In March 2020, Biohaven announced that it was ready to advance intranasal … [Read more...] about Royalty Pharma provides funding for Biohaven’s zavegepant development program

An RA Capital Management company called Aerovate Therapeutics has raised $72.6 million in Series A financing for development of its AV-101 dry powder imatinib for the treatment of pulmonary arterial hypertension (PAH), the company said. A registrational study of AV-101 is expected to begin by mid-2021. According to the announcement, "The concept and proprietary … [Read more...] about Aerovate Therapeutics raises $72.6 million for development of imatinib DPI for PAH